Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. (Q51566310)

7 April 2018

title

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. (English)

1 reference

7 April 2018

1 reference

Avena R

1

1 reference

7 April 2018

Mitchell ME

2

1 reference

7 April 2018

Nylen ES

3

1 reference

7 April 2018

Curry KM

4

1 reference

7 April 2018

Sidawy AN

5

1 reference

7 April 2018

publication date

1 December 1998

1 reference

7 April 2018

Journal of Vascular Surgery

published in

1 reference

7 April 2018

volume

28

1 reference

7 April 2018

issue

6

1 reference

7 April 2018

page(s)

1024-31; discussion 1031-2

1 reference

7 April 2018

Vascular reactivity in patients with peripheral vascular disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Reactive hyperemia unmasks reduced compliance of cutaneous arteries in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Endothelial dysfunction: cause of the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

The effect of occult diabetic status and oral glucose intake on brachial artery vasoactivity in patients with peripheral vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Insulin and atheroma. 20-yr perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Insulin resistance and arteriosclerosis obliterans in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Insulin resistance implications for type II diabetes mellitus and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

International criteria for the diagnosis of diabetes and impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Transforming growth factor beta 1 inhibits the proliferative effect of insulin on human infragenicular vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

The additive effects of glucose and insulin on the proliferation of infragenicular vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Clinical implications of insulin resistance syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Insulin antagonistic effects of insulin receptor antibodies on plasma membrane (Ca2+ + Mg2+) ATPase activity: a possible etiology of type B insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Nitric oxide release accounts for insulin's vascular effects in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2898%2970028-X

7 January 2021

10.1016/S0741-5214(98)70028-X

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

9845653

1 reference

7 April 2018